Analysis of binding affinities for celecoxib analogues with COX-1 and COX-2 from combined docking and Monte Carlo simulations and insight into the COX-2/COX-1 selectivity

被引:130
|
作者
Price, MLP [1 ]
Jorgensen, WL [1 ]
机构
[1] Yale Univ, Dept Chem, New Haven, CT 06520 USA
关键词
D O I
10.1021/ja001018c
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The origins of binding affinity and COX-2/COX-1 selectivity for analogues of celecoxib have been explored using an approach that combines docking with Monte Carlo (MC) simulations. These inhibitors are COX-2-selective nonsteroidal antiinflammatory drugs (NSAIDs) that are of current interest because the gastrointestinal irritation they cause is reduced compared to that caused by traditional NSAIDs. We report a novel docking method, based on a combined Tabu and Monte Carlo protocol, that determines starting conformations for MC simulations. Using the docking-predicted starting conformations, relative changes in binding free energies were computed for methyl, ethyl, hydroxymethyl, hydroxyl, thiomethyl, methoxy, trifluoromethyl, chloro, fluoro, and unsubstituted derivatives with the MC free energy perturbation (FEP) method. The computed free energies are in good accord with IC50 values, and the structural information from the simulations can be used to explain the experimentally observed binding trends. In addition, the docking and FEP results have provided clarification of the binding conformation of the phenylsulfonamide moiety and the origin of COX-2/COX-1 selectivity. Namely, the COX-2 Val --> COX-1 Ile subtitution is accompanied by an unfavorable conformational shift of the phenylsulfonamide ring.
引用
收藏
页码:9455 / 9466
页数:12
相关论文
共 50 条
  • [1] Origin of binding selectivity for celecoxib analogs with COX-1 and COX-2 from combined docking and Monte Carlo simulations.
    Price, MLP
    Jorgensen, WL
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 220 : U286 - U286
  • [2] Rationale for the observed COX-2/COX-1 selectivity of celecoxib from Monte Carlo simulations
    Price, MLP
    Jorgensen, WL
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (12) : 1541 - 1544
  • [3] Roles of COX-1 and COX-2
    McCormack, K
    JOURNAL OF RHEUMATOLOGY, 1998, 25 (11) : 2279 - 2280
  • [4] COX-1 and COX-2 inhibitors
    Hawkey, CJ
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2001, 15 (05) : 801 - 820
  • [5] Evaluation of COX-1/COX-2 selectivity and potency of a new class of COX-2 inhibitors
    Gierse, James
    Nickols, Maureen
    Leahy, Kathleen
    Warner, James
    Zhang, Yan
    Cortes-Burgos, Luz
    Carter, Jeffery
    Seibert, Karen
    Masferrer, Jaime
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 588 (01) : 93 - 98
  • [6] The COX-1/COX-2 balance in asthma
    Pang, L
    Pitt, A
    Petkova, D
    Knox, AJ
    CLINICAL AND EXPERIMENTAL ALLERGY, 1998, 28 (09): : 1050 - 1058
  • [7] Roles of COX-1 and COX-2 - Reply
    de Brum-Fernandes, AJ
    JOURNAL OF RHEUMATOLOGY, 1998, 25 (11) : 2280 - 2281
  • [8] COX-1, COX-2: So what?
    Emery, P
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1999, 28 (01) : 6 - 9
  • [9] Distinct functions of COX-1 and COX-2
    Morita, I
    PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2002, 68-9 : 165 - 175
  • [10] COX-1 and COX-2 products in the gut: therapeutic impact of COX-2 inhibitors
    Whittle, BJR
    GUT, 2000, 47 (03) : 320 - 325